Tokyo Tape
Sign in
← Fuso Pharmaceutical Industries

Annual report

4538.TEDINET S100TRL6
Period2023-04-01 → 2024-03-31
Filed2024-06-25
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 88
MetricValuePeriodScopeSource row
Revenue¥55.4bn2023-04-01 → 2024-03-31StandaloneNet sales
Revenue¥51.0bn2022-04-01 → 2023-03-31StandaloneNet sales
Revenue¥49.6bn2021-04-01 → 2022-03-31dStandaloneNet sales (5-year summary)
Revenue¥49.3bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Revenue¥46.9bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Operating income¥2.0bn2023-04-01 → 2024-03-31StandaloneOperating income
Operating income¥2.2bn2022-04-01 → 2023-03-31StandaloneOperating income
Ordinary income¥1.9bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥2.2bn2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥2.0bn2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥2.2bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥1.1bn2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥1.8bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Profit before tax¥2.2bn2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Net income¥1.4bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥1.6bn2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥1.5bn2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Net income¥1.6bn2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Net income¥707m2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Total assets¥75.8bnat 2024-03-31StandaloneAssets
Total assets¥72.5bnat 2023-03-31StandaloneAssets
Total assets¥69.3bnat 2022-03-31dStandaloneTotal assets (5-year summary)
Total assets¥69.9bnat 2021-03-31dStandaloneTotal assets (5-year summary)
Total assets¥69.2bnat 2020-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥39.1bnat 2024-03-31StandaloneLiabilities
Total liabilities¥36.8bnat 2023-03-31StandaloneLiabilities
Net assets / equity¥36.7bnat 2024-03-31StandaloneNet assets
Net assets / equity¥35.6bnat 2023-03-31StandaloneNet assets
Net assets / equity¥34.5bnat 2022-03-31dStandaloneNet assets
Net assets / equity¥33.7bnat 2021-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥32.3bnat 2020-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥5.1bnat 2024-03-31StandaloneCash and deposits
Cash and deposits¥8.0bnat 2023-03-31StandaloneCash and deposits
Cash & equivalents¥5.1bnat 2024-03-31StandaloneCash and cash equivalents
Cash & equivalents¥8.0bnat 2023-03-31StandaloneCash and cash equivalents
Cash & equivalents¥7.3bnat 2022-03-31dStandaloneCash and cash equivalents
Cash & equivalents¥7.1bnat 2021-03-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥7.3bnat 2020-03-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow¥627m2023-04-01 → 2024-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥2.9bn2022-04-01 → 2023-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥3.5bn2021-04-01 → 2022-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.2bn2020-04-01 → 2021-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.7bn2019-04-01 → 2020-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥3.5bn2023-04-01 → 2024-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥1.4bn2022-04-01 → 2023-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥1.6bn2021-04-01 → 2022-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥978m2020-04-01 → 2021-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.5bn2019-04-01 → 2020-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥14m2023-04-01 → 2024-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥813m2022-04-01 → 2023-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥1.7bn2021-04-01 → 2022-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥2.4bn2020-04-01 → 2021-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.8bn2019-04-01 → 2020-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥159.982023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥183.072022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥169.092021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥183.182020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥80.592019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥702023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥702022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥602021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥602020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥602019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥4,290.55at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥4,064.76at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥3,936.7at 2022-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥3,839.54at 2021-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥3,681.46at 2020-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio48.4%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio49.2%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio49.8%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio48.2%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio46.7%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE3.8%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE4.6%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE4.3%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
ROE4.9%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
ROE2.2%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued9,451,169at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees1,307at 2024-03-31StandaloneNumber of employees
Employees1,314at 2023-03-31StandaloneNumber of employees
Employees1,344at 2022-03-31dStandaloneNumber of employees
Employees1,356at 2021-03-31dStandaloneNumber of employees
Employees1,352at 2020-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 2
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2024-03-311247 pure
Real Estate Businessreportable segmentemployeesat 2024-03-311 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,027
ItemContextValueUnit
Noncurrent liabilitiesCurrentYearInstant_NonConsolidatedMember9489000000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember36817000000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember39140000000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember10758000000JPY
Capital stockCurrentYearInstant_NonConsolidatedMember10758000000JPY
Legal capital surplusPrior1YearInstant_NonConsolidatedMember10000000000JPY
Legal capital surplusCurrentYearInstant_NonConsolidatedMember10000000000JPY
Other capital surplusPrior1YearInstant_NonConsolidatedMember5009000000JPY
Other capital surplusCurrentYearInstant_NonConsolidatedMember4951000000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember15009000000JPY
Capital surplusCurrentYearInstant_NonConsolidatedMember14951000000JPY
General reservePrior1YearInstant_NonConsolidatedMember5300000000JPY
General reserveCurrentYearInstant_NonConsolidatedMember5300000000JPY
Retained earnings brought forwardPrior1YearInstant_NonConsolidatedMember10511000000JPY
Retained earnings brought forwardCurrentYearInstant_NonConsolidatedMember11241000000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember15811000000JPY
Retained earningsCurrentYearInstant_NonConsolidatedMember16541000000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-2173000000JPY
Treasury stockCurrentYearInstant_NonConsolidatedMember-2588000000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember39405000000JPY
Shareholders equityCurrentYearInstant_NonConsolidatedMember39662000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant_NonConsolidatedMember879000000JPY
Valuation difference on available for sale securitiesCurrentYearInstant_NonConsolidatedMember1634000000JPY
Revaluation reserve for landPrior1YearInstant_NonConsolidatedMember-4635000000JPY
Revaluation reserve for landCurrentYearInstant_NonConsolidatedMember-4635000000JPY
Valuation and translation adjustmentsPrior1YearInstant_NonConsolidatedMember-3756000000JPY
Valuation and translation adjustmentsCurrentYearInstant_NonConsolidatedMember-3000000000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember35649000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember36661000000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember72466000000JPY
Liabilities and net assetsCurrentYearInstant_NonConsolidatedMember75802000000JPY
Net sales on medicine business rev oaPrior1YearDuration_NonConsolidatedMember50840000000JPY
Net sales on medicine business rev oaCurrentYearDuration_NonConsolidatedMember55245000000JPY
Rent income of real estate rev oaPrior1YearDuration_NonConsolidatedMember175000000JPY
Rent income of real estate rev oaCurrentYearDuration_NonConsolidatedMember161000000JPY
Net salesPrior1YearDuration_NonConsolidatedMember51015000000JPY
Net salesCurrentYearDuration_NonConsolidatedMember55407000000JPY
Cost of sales on medicine business cos exp oaPrior1YearDuration_NonConsolidatedMember37187000000JPY
Cost of sales on medicine business cos exp oaCurrentYearDuration_NonConsolidatedMember41445000000JPY
Cost of real estate rent cos exp oaPrior1YearDuration_NonConsolidatedMember87000000JPY
Cost of real estate rent cos exp oaCurrentYearDuration_NonConsolidatedMember122000000JPY
Cost of salesPrior1YearDuration_NonConsolidatedMember37275000000JPY
Cost of salesCurrentYearDuration_NonConsolidatedMember41568000000JPY
Gross profitPrior1YearDuration_NonConsolidatedMember13740000000JPY
Gross profitCurrentYearDuration_NonConsolidatedMember13838000000JPY
Selling general and administrative expensesPrior1YearDuration_NonConsolidatedMember11533000000JPY
Selling general and administrative expensesCurrentYearDuration_NonConsolidatedMember11874000000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember2206000000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember1964000000JPY
Interest and dividends income noiPrior1YearDuration_NonConsolidatedMember89000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2023-03-31pass
balance sheet identitynon_consolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · operating cash flownon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flownon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass